Methylprednisolone

CAS No:
83-43-2 Category:
  • #LGM Pharma is a Methylprednisolone CAS# 83-43-2 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 83-43-2
  • AHFC code: 08:04.0
  • Synonyms: 6alpha-Methylprednisolone Methyleneprednisolone Methylprednisolon Methylprednisolonum [INN-Latin] Metilprednisolona [INN-Spanish] Metilprednisolone [Dcit]
  • ATC Code: D07AA01 D07AC14 D10AA02 H02AB04
  • Chemical Formula: C29H38FN3O3
  • Molecular Weight: 374.4706
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00959 (APRD00342)
  • SMILES: C[C,H]1C[C,H]2[C,,H]3CC[C,](O)(C(=O)CO)[C,,]3(C)C[C,H](O)[C,,H]2[C,,]2(C)C=CC(=O)C=C12
  • InChl: VHRSUDSXCMQTMA-PJHHCJLFSA-N
  • PubChem: 6741
  • IUPAC: (1S,2R,8S,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,8,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one

Additional Details

Indication:
Adjunctive therapy for short-term administration in rheumatoid arthritis.
Pharmacodynamics:
Methylprednisolone and its derivatives, methylprednisolone sodium succinate and methylprednisolone acetate, are synthetic glucocorticoids used as antiinflammatory or immunosuppressive agents.
Mode of Action:
Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Metabolism:
Hepatic
Toxicity:
LD50=2000 mg/kg (orally in rat)
General Reference:
Sloka JS, Stefanelli M: The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler. 2005 Aug;11(4):425-32. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos